In comparison with the majority of the studies investigating the biodistribution of radiolabelled HER2 targeting monoclonal antibodies, the radioconjugate 225Ac-PD2 demonstrates high uptake in HER2+ tumour and similarly low uptake in both HER2- tumour and healthy tissues with spleen uptake being the most variable. This evidence concerns the gene PAF1 and neoplasm.